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Abstract: 
 
Primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial 
infarction (STEMI) due to saphenous vein graft (SVG) occlusion has been associated with poor 
procedural results and poor short-term outcomes, but long-term graft patency and patient 
survival have not been evaluated. Consecutive patients (n = 2,240) with STEMI treated with 
primary PCI from 1984 to 2003 were followed for 6.6 years (median). Follow-up angiography 
was obtained in 80% of hospital survivors following primary PCI for SVG occlusion at 2.3 years 
(median). Patients with primary PCI for SVG occlusion (n = 57) vs. native artery occlusion had 
more prior MI, advanced Killip class, and three-vessel coronary disease and lower acute ejection 
fraction (EF). Patients with SVG occlusion had lower rates of TIMI 3 flow post-PCI (80.7% vs. 
93.6%; P = 0.0001), higher in-hospital mortality (21.1% vs. 8.0%; P = 0.0004), and lower 
follow-up EF (49.3% vs. 54.7%; P = 0.055). Culprit SVGs were patent in 64% of patients at 1 
year and 56% at 5 years. Late survival was strikingly worse in patients with primary PCI for 
SVG occlusion vs. native vessel occlusion (49% vs. 76% at 10 years), and SVG occlusion was 
the second strongest predictor of late cardiac mortality by multivariate analysis (HR = 2.11; 95% 
CI = 1.38–3.23; P = 0.0006). Patients with STEMI due to SVG occlusion treated with primary 
PCI have poor acute procedural results, frequent late reocclusion, and very high late mortality. 
The introduction of new adjunctive therapies (distal protection, thrombectomy, and drug-eluting 
stents) may improve short-term outcomes, but improved long-term outcomes may require new 
and more durable revascularization strategies.  
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Article:  
 
INTRODUCITON 
 
Patients with prior coronary bypass surgery represent an increasing proportion of patients with 
ST segment elevation acute myocardial infarction (STEMI) [1] Attempts at establishing 
reperfusion of occluded saphenous vein grafts (SVG) with thrombolytic therapy have not been 
very effective [2], and mechanical reperfusion with primary percutaneous coronary intervention 
(PCI) has become the preferred reperfusion strategy. Despite potential advantages, mechanical 
reperfusion of occluded SVGs is frequently complicated by distal embolization and no-reflow, 
and procedural outcomes and short-term clinical outcomes have been much worse than for 
mechanical reperfusion of occluded native vessels [3–5]. Late outcomes following primary PCI 
for STEMI due to SVG occlusion have not been well defined. The purpose of this study is to 
examine our large database of patients with STEMI treated with primary PCI to compare late 
cardiac survival and late graft survival in patients with SVG occlusion vs. native vessel 
occlusion. 
 
MATERIALS AND METHODS 
 
Study Population 
 
Our study population consists of 2,240 consecutive patients with STEMI treated with primary 
PCI without prior thrombolytic therapy at our institution from 1984 to 2003. Patients with chest 
pain of < 12 hr duration (> 12 hr for persistent pain or hemodynamic compromise), with 
electrocardiographic ST segment elevation _ 1 mm in _ 2 contiguous leads or left bundle branch 
block, and without severe comorbid disease were selected for intervention. 
 
Treatment Protocol 
 
Patients were treated with heparin and aspirin in the emergency department and transferred 
promptly to the catheterization laboratory for mechanical reperfusion. Stents were first used in 
1995 and overall were used in 33% of patients. Platelet glycoprotein IIb/IIIa inhibitors were first 
used in 1996 and overall were used in 29% of patients. Ticlopidine or clopidogrel were used in 
stented patients and were continued for at least 1 month. b-adrenergic blocking agents and 
nitrates were initially used at the operator’s discretion and became standard treatment in the later 
years of the study. 
 
Clinical and Angiographic Follow-Up 
 
Clinical follow-up was obtained by hospital and office chart review and telephone contact in 
96% of hospital survivors at a median follow-up time of 6.6 years. Follow-up angiography was 
performed routinely during the first 3 years of the study and during participation in several 
clinical trials, or for recurrent ischemic symptoms or after abnormal functional testing. 
Follow-up angiography was obtained in 80% of hospital survivors with primary PCI for SVG 
occlusion at a median follow-up time of 2.3 years. 
 
Definitions and Data Analysis 
 
Time to reperfusion was defined as the time from the onset of symptoms until balloon inflation. 
Coronary flow in the infarct artery was assessed visually by the operator and classified according 
to TIMI grading system on a scale of 0 to 3 [6]. Reinfarction was defined as recurrent chest pain 
associated with any secondary rise in the creatine kinase level and the MB fraction higher than 
the nadir, with or without diagnostic electrocardiographic changes. Urgent target vessel 
revascularization was defined as the need for repeat PCI or bypass surgery for recurrent ischemia 
or hemodynamic compromise. 
 
Left ventricular ejection fractions were calculated from tracing contours of right anterior oblique 
cine angiograms using the area-length method with correction for the right anterior oblique 
projection [7]. 
 
Statistical Analysis 
 
Statistical comparisons of categorical variables were performed using the chi-square test or 
Fisher’s exact test. Student’s unpaired t-test was used for comparing continuous variables. 
Differences in late graft patency by type of graft and differences in late cardiac survival between 
patients with native artery vs. SVG occlusion were examined with Kaplan-Meier survival curves 
and their associated Wilcoxon statistics. Multivariable analyses of predictors of late cardiac 
survival were performed using Cox proportional hazards regression models. All clinical variables 
in Table I plus infarct artery type (SVG vs. native artery) were entered into the model. All 
analyses were performed with SAS (Cary, NC) and SPSS (Chicago, IL) software. 
 
RESULTS 
 
Baseline Variables 
 
Of the 2,240 patients in our study cohort, 107 had prior coronary bypass surgery. The infarct 
vessel was a native coronary artery in 50 of these patients and an SVG in 57 patients (Table I). 
The median time from bypass surgery to the index myocardial infarction in patients with primary 
PCI for SVG occlusion was 9.8 years. Patients with primary PCI for SVG vs. native artery 
occlusion were slightly older, more often male, and had a higher frequency of prior infarction, 
Killip class 3–4, and three-vessel coronary artery disease and had lower acute left ventricular 
ejection fraction (Table I). 
 
Procedural and In-Hospital Outcomes 
 
Patients with primary PCI for SVG vs. native vessel occlusion had a significantly lower 
frequency of TIMI 3 flow post-PCI and a significantly higher in-hospital mortality (Table II). 
There were no differences in reinfarction, urgent target vessel revascularization, or stroke, and no 
differences in infarct size based on peak creatine kinase and the MB fraction. Left ventricular 
ejection fraction at follow-up angiography was lower in patients with PCI for SVG occlusion. 
 
Late Graft Patency 
 
Graft survival following primary PCI for STEMI due to SVG occlusion was poor (Fig. 1). The 
culprit infarct SVG was patent in 64% of patients at 1 year and 56% at 5 years. Patency of the 
culprit SVG was better in stented (n = 19) vs. nonstented (n = 37) patients at 5 years (80% vs. 
45%; P = 0.053).  
 
Noninfarct SVGs (n ¼ 75) were patent in 58% of patients at 1 year and 58% at 5 years (Fig. 1). 
Left internal mammary grafts (used in 26 patients) remained patent in 95% of patients at 5 years.  
 
Graft survival free of target vessel revascularization (TVR) was also very poor for both culprit 
and nonculprit SVGs (Fig. 2). The culprit infarct SVG was free of occlusion or TVR in 38% of 
patients at 1 year and 17% at 5 years. Noninfarct SVGs were free of occlusion or TVR in 45% of 
patients at 1 year and 33% at 5 years. Left internal mammary grafts were free of occlusion or 
TVR in 95% of patients at 5 years. 
 
 
 
 
 
Late Cardiac Survival 
 
Late cardiac survival was significantly and strikingly worse in patients whose infarct artery was 
an SVG vs. a native coronary artery (49% vs. 76% at 10 years) with survival curves that 
diverged over time (Fig. 3). After adjusting for differences in baseline variables, primary PCI for 
SVG occlusion (vs. native artery occlusion) was the second strongest predictor of late cardiac 
mortality (Table III). After further adjusting for procedural outcomes (TIMI flow post-PCI), 
SVG occlusion remained a significant predictor of late cardiac mortality (hazard ratio ¼ 2.01; 
95% CI ¼ 1.32–3.08; P ¼ 0.001). 
 
Seven of the 57 patients with primary PCI for SVG occlusion underwent repeat bypass surgery 
during their hospital stay. There were no differences in late cardiac survival between patients 
who underwent repeat bypass surgery and those who did not. 
 
DISCUSSION 
 
Patients with prior coronary bypass surgery who present with STEMI due to SVG occlusion 
offer a than the progression of disease in patients following bypass surgery who have not 
suffered an acute myocardial infarction. In prior studies, SVG patency following coronary 
bypass surgery has been estimated at 88% at 1 year, followed by an occlusion rate of 2.1% per 
year [8,9]. 
 
 
 
 
 
Our study shows that late cardiac survival following primary PCI for STEMI due to SVG 
occlusion is strikingly worse compared with primary PCI for native coronary artery occlusion 
with survival curves that diverge over time. There appear to be several reasons for this. First, 
patients with SVG occlusion have a higher baseline risk profile with more advanced age, more 
prior infarction, more frequent advanced Killip class, more three-vessel coronary disease, and 
lower acute ejection fraction. Second, procedural outcomes are worse with lower rates of TIMI 3 
flow following PCI. Finally, long-term graft survival is very poor following primary PCI for 
SVG occlusion. This is likely related to both reocclusion at the PCI site and progression of 
disease at other sites in the SVG. After adjusting for differences in baseline variables, SVG 
occlusion was the second strongest independent predictor of late cardiac mortality. After further 
adjusting for procedural outcomes (TIMI flow), SVG occlusion remained an independent 
predictor of late cardiac mortality. This suggests that poor graft survival contributes to the high 
late cardiac mortality. Previous studies evaluating outcomes following elective PCI for SVG 
obstruction have shown a high frequency of late adverse events [10]. Our study indicates that late 
events following emergent PCI for STEMI due to SVG occlusion are substantially worse than 
after elective PCI. 
 
Study Limitations 
 
Although all data were collected prospectively, our study is single-center and observational. 
Follow-up angiography was not prespecified and was obtained primarily for clinical indications. 
Our study spans almost 20 years; consequently, most of our patients did not have the latest 
adjunctive therapy used with primary PCI. Stents were used in 33% of patients, distal protection 
in three patients, thrombectomy in two patients, and drug-eluting stents were not used. 
 
 
 
Clinical Implications 
 
The very poor procedural outcomes and poor short and long-term clinical outcomes should 
stimulate new therapies for patients with STEMI due to SVG occlusion. Already, there have 
been a number of new interventional therapies introduced to help improve procedural outcomes. 
Distal protection devices (PercuSurge GuardWire, Medtronic, and FilterWire, Boston Scientific) 
have been shown to be effective in elective PCI in SVGs and may also improve outcomes with 
primary PCI of occluded SVGs [11,12]. Short-term and possibly long-term outcomes in our 
patients may have been improved if distal protection devices had been available and were able to 
be used more frequently. Thrombectomy (Possis Angiojet; Possis) has been shown to be 
effective as adjunctive therapy with PCI in thrombus containing lesions and may help in patients 
with STEMI due to SVG occlusion [13]. Drug-eluting stents reduce restenosis and TVR after 
elective PCI in native vessels and may be useful with primary PCI for occluded SVGs. More 
frequent use of stents and the use of drug-eluting stents would likely have improved late 
outcomes in our study cohort. Platelet glycoprotein IIb/IIIa inhibitors may offer some benefit in 
these patients with thrombus containing lesions, although there appears to be no benefit when 
used with elective PCI for SVG occlusion [14]. 
 
The poor late outcomes in patients treated with percutaneous intervention for SVG occlusion 
might encourage a more aggressive approach with surgical revascularization prior to hospital 
discharge. Unfortunately, this approach is often limited by comorbidities preventing repeat 
operation; in our limited experience, we were not able to document any improvement in 
outcomes with this approach. 
 
More aggressive treatment with secondary prevention after the initial bypass procedure may help 
prevent or delay the occurrence of acute infarction, and aggressive secondary prevention after 
acute infarction may help improve subsequent outcomes. In addition to aspirin, b-blockers, and 
angiotensin-converting enzyme inhibitors, cholesterol-lowering therapy with statin medications 
and platelet inhibition with clopidogrel have been shown to be especially beneficial in patients 
with prior bypass surgery [15,16]. 
 
Despite these advances in therapy, once SVG disease becomes evident, usually there is 
accelerated progression of disease. This is likely a major factor, along with higher baseline risk 
profile and worse procedural outcomes, that contributes to poor long-term survival. Although we 
may achieve some improvement in outcomes with new procedural techniques and more 
aggressive secondary prevention, major improvements in outcomes will require more durable 
revascularization strategies. 
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